Drugs / Anecatibin
Anecatibin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07538973 | Apr 2026 → Mar 2027 expected | lung cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anecatibin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07538973 ↗ |
| Known as | Anecatibin fumarate | “Anecatibin fumarate capsule is a prodrug that can be rapidly hydrolyzed into crizotinib in vivo to exert pharmacodynamic effects.” NCT07538973 ↗ |
| Known as | Anecatibin Fumarate Capsules | “Anecatibin Fumarate Capsules (TQ-B3101 Capsules)” NCT07538973 ↗ |
| Known as | TQ-B3101 Capsules | “Anecatibin Fumarate Capsules (TQ-B3101 Capsules)” NCT07538973 ↗ |